Category

Archives

S1P Receptor

Development and validation of an MRI-based radiomics nomogram for distinguishing Warthin's tumour from pleomorphic adenomas of the parotid gland

153 views | May 07 2021

Ying-Mei Zheng et al. found that the MRI-based radiomics nomogram had good performance in distinguishing parotid WT from PMA, which could optimize clinical decision-making. [Read the Full Post]

A fluorometric erythrophagocytosis assay using differentiated monocytic THP-1 cells to assess the clinical significance of antibodies to red blood cells

159 views | May 06 2021

Abdelwahab Hassan Ahmed Balola et al. thought that the flow cytometry-based erythrophagocytosis test described here was quantitative, highly reliable, and might be helpful for the assessment of the clinical significance of antibodies to RBCs. [Read the Full Post]

Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543

546 views | Jun 06 2018

Ju T et al. found that mitochondrial programmed necrosis pathway is likely the key mechanism responsible for PF-543's actions in CRC cells. [Read the Full Post]

Sphingosine kinase inhibition ameliorates chronic hypoperfusion-induced white matter lesions

758 views | Nov 10 2017

Yang Y et al. suggested a mechanism for hypoperfusion-associated WML involving HIF-1α-SphK2-S1P-mediated disruption of OPC differentiation, and proposes the SphK signaling pathway as a potential therapeutic target for white matter disease. [Read the Full Post]

Cytokine correlation analysis based on drug perturbation

3012 views | Oct 17 2017

Wallner FK et al. showed that cytokines are highly co-regulated, which provide valuable information for how a therapeutic drug might affect clusters of cytokines. In addition, a cytokine that is used as a therapeutic biomarker could be combined with its related cytokines into a biomarker panel to improve diagnostic accuracy. [Read the Full Post]

FTY720 is a first in class orally bioavailable

2479 views | Feb 24 2014

The inhibitory effect of S1P is revered by various concentrations of FTY720. [Read the Full Post]

FTY720 is a first in class orally bioavailable compound

2470 views | Nov 05 2013

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. [Read the Full Post]

FTY720 is phosphorylated by sphingosine kinase type 2

2768 views | Sep 30 2013

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. [Read the Full Post]

FTY720 is an immunomodulating drug, approved for treating multiple sclerosis

3020 views | Jun 03 2013

Fingolimod is a sphingosine 1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. [Read the Full Post]

FTY720 – THE IMMUNE CELLS CONTROLLER

2883 views | Apr 11 2012

FTY720: One of the extensively used immunoregulatory drug is Fingolimod, FTY720 is the code for this drug and it is a product of Novartis. The properties like anti-tumor actions and immunosuppressant activities made FTY720 Fingolimod a new hope against the debilitating diseases such as Multiple Sclerosis. FTY720 price for 100mg is around $40. Like many other compounds it is not soluble in water but a reasonable solubility of concentration of 100mg/ml can be attained using organic solvents such as DMSO and ethanol. Structurally FTY720 is an analogue of sphingosine molecule due to which this molecule has the capability to act on sphingosine-1-phosphate receptor, this report has been confirmed by gene deletion and reverse pharmacology studies. Various chemical modifications have been made with FTY720 in order to enhance its efficiency and to take it in clinical trials based on different diseases. If anyone wants to purchase FTY720 for laboratory and clinical uses one can order FTY720 to any FTY720 suppliers. IC50 of this drug is about 0.13 nM. [Read the Full Post]